Zydus Healthcare

Zydus is a fully integrated, global healthcare provider, with strengths all along the pharmaceutical value chain. With a core competence in the field of healthcare, Zydus provides total healthcare solutions ranging from formulations, active pharmaceutical ingredients to wellness products. Zydus ranks among the top 10 pharmaceutical companies in India and has a strong presence in over 100 countries worldwide. Its the only Indian Pharma company to launch its own patented NCE-Lipaglyn, the world’s first drug to be approved for the treatment of diabetic dyslipidemia and for treatment of NASH. Zydus has also launched Exemptia, the world’s first biosimilar for Adalimumab, the largest selling therapy worldwide for inflammatory arthritis. Zydus Healthcare Limited, the branded formulations arm of the group, plays a vital role in the company’s domestic growth. It offers a diverse portfolio of 350+ brands across 15+ therapy areas—including cardiology, diabetology, dermatology, gastroenterology, pain management, gynecology, nephrology, and wellness.